vatalanib

Known as: 1-(4-chloroanilino)-4-(pyridylmethyl)phthalazine, N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine, PTK/ZK 
An orally bioavailable anilinophthalazine with potential antineoplastic activity. Vatalanib binds to and inhibits the protein kinase domain of… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2017
0102020012017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
INTRODUCTION The Cancer and Leukemia Group B (CALGB) conducted a multi-center phase II trial to evaluate the efficacy and safety… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
PURPOSE The Colorectal Oral Novel therapy For the Inhibition of angiogenesis and Retarding of Metastases (CONFIRM)-randomized… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE Comparison of the antiangiogenic/vascular properties of the oral mammalian target of rapamycin (mTOR) inhibitor RAD001… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2006
2006
Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2006
2006
3508 Background: PTK/ZK is a novel, oral, small molecule, antiangiogenic compound that inhibits tyrosine kinase signaling of all… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND Plasma and serum biomarkers of angiogenesis and activated endothelial cells were evaluated to assess biological… (More)
  • table 1
  • figure 1
  • table 3
  • table 2
  • figure 2
Is this relevant?
Highly Cited
2005
Highly Cited
2005
PURPOSE PTK787/ZK 222584 (PTK/ZK) is an oral angiogenesis inhibitor targeting all known vascular endothelial growth factor (VEGF… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
The family of VEGF receptors are important mediators of angiogenesis, which is essential for tumour growth and metastasis. PTK/ZK… (More)
Is this relevant?
2005
2005
Assessment of tumour vascularity may characterize malignancy as well as predict responsiveness to anti-angiogenic therapy. Non… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
PURPOSE PTK787/ZK 222584 (PTK/ZK), an orally active inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine… (More)
Is this relevant?